Company Of The Day: Pfizer

+3.09%
Upside
27.75
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) said that the U.S. FDA granted the company’s vaccine candidate targeted at respiratory syncytial virus PF-06928316 (RSVpreF) a Breakthrough Therapy designation.

Why?

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

The Breakthrough Therapy designation is meant to speed up the development and review process for treatments focused on serious or life-threatening conditions. The agency’s decision is based on a proof-of-concept Phase 2a study carried out by Pfizer.

So What?

The market for an RSV vaccine could be sizable, as there are currently no therapeutic or preventive options available for older adults with the disease. RSV is estimated to cause around 14,000 deaths in the U.S. every year.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Mar 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 12% -11% 62%
 S&P 500 Return 2% -7% 99%
 Trefis MS Portfolio Return 2% -9% 259%

[1] Month-to-date and year-to-date as of 3/25/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates